Unknown

Dataset Information

0

Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells.


ABSTRACT: BCR/ABL1 causes dysregulated cell proliferation and is responsible for chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL). In addition to the deregulatory effects of its kinase activity on cell proliferation, BCR/ABL1 induces genomic instability by downregulating BRCA1. PARP inhibitors (PARPi) effectively induce cell death in BRCA-defective cells. Therefore, PARPi are expected to inhibit growth of CML and Ph1-ALL cells showing downregulated expression of BRCA1. Here, we show that PARPi effectively induced cell death in BCR/ABL1 positive cells and suppressed colony forming activity. Prevention of BCR/ABL1-mediated leukemogenesis by PARP inhibition was tested in two in vivo models: wild-type mice that had undergone hematopoietic cell transplantation with BCR/ABL1-transduced cells, and a genetic model constructed by crossing Parp1 knockout mice with BCR/ABL1 transgenic mice. The results showed that a PARPi, olaparib, attenuates BCR/ABL1-mediated leukemogenesis. One possible mechanism underlying PARPi-dependent inhibition of leukemogenesis is increased interferon signaling via activation of the cGAS/STING pathway. This is compatible with the use of interferon as a first-line therapy for CML. Because tyrosine kinase inhibitor (TKI) monotherapy does not completely eradicate leukemic cells in all patients, combined use of PARPi and a TKI is an attractive option that may eradicate CML stem cells.

SUBMITTER: Hiroki H 

PROVIDER: S-EPMC10172294 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

altmetric image

Publications


BCR/ABL1 causes dysregulated cell proliferation and is responsible for chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1-ALL). In addition to the deregulatory effects of its kinase activity on cell proliferation, BCR/ABL1 induces genomic instability by downregulating BRCA1. PARP inhibitors (PARPi) effectively induce cell death in BRCA-defective cells. Therefore, PARPi are expected to inhibit growth of CML and Ph1-ALL cells showing downregul  ...[more]

Similar Datasets

| S-EPMC2955921 | biostudies-literature
| S-EPMC7880371 | biostudies-literature
| S-EPMC3676346 | biostudies-literature
| S-EPMC4059819 | biostudies-literature
| S-EPMC10953774 | biostudies-literature
| S-EPMC2797163 | biostudies-literature
| S-EPMC3771348 | biostudies-literature
| S-EPMC7062869 | biostudies-literature
| S-EPMC4123609 | biostudies-literature
| S-EPMC7038108 | biostudies-literature